Skip to main content
Top
Gepubliceerd in:

17-09-2018

Validity of the EQ-5D-5L and EQ-5D-3L in patients with Crohn’s disease

Auteurs: Fanni Rencz, Peter L. Lakatos, László Gulácsi, Valentin Brodszky, Zsuzsanna Kürti, Szilvia Lovas, János Banai, László Herszényi, Tamás Cserni, Tamás Molnár, Márta Péntek, Károly Palatka

Gepubliceerd in: Quality of Life Research | Uitgave 1/2019

Log in om toegang te krijgen
share
DELEN

Deel dit onderdeel of sectie (kopieer de link)

  • Optie A:
    Klik op de rechtermuisknop op de link en selecteer de optie “linkadres kopiëren”
  • Optie B:
    Deel de link per e-mail

Abstract

Purpose

The EuroQol five-dimension questionnaire (EQ-5D) is the most commonly used instrument to obtain utility values for cost-effectiveness analyses of treatments for Crohn’s disease (CD). We aimed to compare the measurement properties of the two adult versions of EQ-5D (EQ-5D-3L and EQ-5D-5L) in patients with CD.

Methods

Between 2016 and 2017, a multicentre cross-sectional survey was carried out. Consecutive outpatients with CD completed the 3L, 5L and EQ visual analogue scale (VAS). Disease severity was graded by the Crohn’s Disease Activity Index (CDAI) and Perianal Disease Activity Index (PDAI). The 3L and 5L were compared in terms of feasibility, agreement, ceiling effect, redistribution properties, discriminatory power, convergent and known-groups validity.

Results

Two-hundred and six patients (54.9% male, mean age 35 ± 11 years) participated in the survey. For 3L, 25 unique health states were observed versus 59 for the 5L. The overall ceiling effect decreased from 29.6% (3L) to 25.5% (5L). Absolute discriminatory power improved (mean Shannon index 0.84 vs. 1.18). The 3L correlated stronger with EQ VAS and CDAI scores, whereas the 5L with PDAI. The 5L demonstrated a better known-groups validity on the basis of age, perianal fistulas, extraintestinal manifestations and disability.

Conclusions

This is the first study to report the impact of CD on quality of life using the EQ-5D-5L questionnaire. The 5L seems to perform better than 3L in terms of feasibility, ceiling effect, discriminatory power and known-groups validity. Understanding the differences in psychometrics between the 3L and 5L is essential as they have substantial implications for financial decision-making about CD treatments.
Literatuur
1.
go back to reference Ng, S. C., Shi, H. Y., Hamidi, N., Underwood, F. E., Tang, W., Benchimol, E. I., et al. (2018). Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: A systematic review of population-based studies. The Lancet, 390(10114), 2769–2778. Ng, S. C., Shi, H. Y., Hamidi, N., Underwood, F. E., Tang, W., Benchimol, E. I., et al. (2018). Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: A systematic review of population-based studies. The Lancet, 390(10114), 2769–2778.
2.
go back to reference Kaplan, G. G. (2015). The global burden of IBD: From 2015 to 2025. Nature Reviews Gastroenterology & Hepatology, 12(12), 720–727. Kaplan, G. G. (2015). The global burden of IBD: From 2015 to 2025. Nature Reviews Gastroenterology & Hepatology, 12(12), 720–727.
3.
go back to reference Torres, J., Mehandru, S., Colombel, J. F., & Peyrin-Biroulet, L. (2017). Crohn’s disease. The Lancet, 389(10080), 1741–1755. Torres, J., Mehandru, S., Colombel, J. F., & Peyrin-Biroulet, L. (2017). Crohn’s disease. The Lancet, 389(10080), 1741–1755.
4.
go back to reference Harbord, M., Annese, V., Vavricka, S. R., Allez, M., Barreiro-de Acosta, M., Boberg, K. M., et al. (2016). The first European evidence-based consensus on extra-intestinal manifestations in inflammatory bowel disease. Journal of Crohn’s and Colitis, 10(3), 239–254.PubMed Harbord, M., Annese, V., Vavricka, S. R., Allez, M., Barreiro-de Acosta, M., Boberg, K. M., et al. (2016). The first European evidence-based consensus on extra-intestinal manifestations in inflammatory bowel disease. Journal of Crohn’s and Colitis, 10(3), 239–254.PubMed
5.
go back to reference van der Have, M., van der Aalst, K. S., Kaptein, A. A., Leenders, M., Siersema, P. D., Oldenburg, B., et al. (2014). Determinants of health-related quality of life in Crohn’s disease: A systematic review and meta-analysis. Journal of Crohn’s and Colitis, 8(2), 93–106.PubMed van der Have, M., van der Aalst, K. S., Kaptein, A. A., Leenders, M., Siersema, P. D., Oldenburg, B., et al. (2014). Determinants of health-related quality of life in Crohn’s disease: A systematic review and meta-analysis. Journal of Crohn’s and Colitis, 8(2), 93–106.PubMed
6.
go back to reference Brodszky, V., Rencz, F., Pentek, M., Baji, P., Lakatos, P. L., & Gulacsi, L. (2016). A budget impact model for biosimilar infliximab in Crohn’s disease in Bulgaria, the Czech Republic, Hungary, Poland, Romania, and Slovakia. Expert Review of Pharmacoeconomics & Outcomes Research, 16(1), 119–125. Brodszky, V., Rencz, F., Pentek, M., Baji, P., Lakatos, P. L., & Gulacsi, L. (2016). A budget impact model for biosimilar infliximab in Crohn’s disease in Bulgaria, the Czech Republic, Hungary, Poland, Romania, and Slovakia. Expert Review of Pharmacoeconomics & Outcomes Research, 16(1), 119–125.
7.
go back to reference Rencz, F., Pentek, M., Bortlik, M., Zagorowicz, E., Hlavaty, T., Sliwczynski, A., et al. (2015). Biological therapy in inflammatory bowel diseases: Access in Central and Eastern Europe. World Journal of Gastroenterology, 21(6), 1728–1737.PubMedPubMedCentral Rencz, F., Pentek, M., Bortlik, M., Zagorowicz, E., Hlavaty, T., Sliwczynski, A., et al. (2015). Biological therapy in inflammatory bowel diseases: Access in Central and Eastern Europe. World Journal of Gastroenterology, 21(6), 1728–1737.PubMedPubMedCentral
8.
go back to reference Boncz, I., & Sebestyen, A. (2006). Financial deficits in the health services of the UK and Hungary. The Lancet, 368(9539), 917–918. Boncz, I., & Sebestyen, A. (2006). Financial deficits in the health services of the UK and Hungary. The Lancet, 368(9539), 917–918.
14.
go back to reference Rencz, F., Gulacsi, L., Drummond, M., Golicki, D., Prevolnik Rupel, V., Simon, J., et al. (2016). EQ-5D in central and eastern Europe: 2000–2015. Quality of Life Research, 25(11), 2693–2710.PubMed Rencz, F., Gulacsi, L., Drummond, M., Golicki, D., Prevolnik Rupel, V., Simon, J., et al. (2016). EQ-5D in central and eastern Europe: 2000–2015. Quality of Life Research, 25(11), 2693–2710.PubMed
15.
go back to reference Rowen, D., Azzabi Zouraq, I., Chevrou-Severac, H., & van Hout, B. (2017). International regulations and recommendations for utility data for health technology assessment. Pharmacoeconomics, 35(Suppl 1), 11–19.PubMed Rowen, D., Azzabi Zouraq, I., Chevrou-Severac, H., & van Hout, B. (2017). International regulations and recommendations for utility data for health technology assessment. Pharmacoeconomics, 35(Suppl 1), 11–19.PubMed
16.
go back to reference Sanders, G. D., Neumann, P. J., Basu, A., Brock, D. W., Feeny, D., Krahn, M., et al. (2016). Recommendations for conduct, methodological practices, and reporting of cost-effectiveness analyses: Second panel on cost-effectiveness in health and medicine. JAMA, 316(10), 1093–1103.PubMed Sanders, G. D., Neumann, P. J., Basu, A., Brock, D. W., Feeny, D., Krahn, M., et al. (2016). Recommendations for conduct, methodological practices, and reporting of cost-effectiveness analyses: Second panel on cost-effectiveness in health and medicine. JAMA, 316(10), 1093–1103.PubMed
18.
go back to reference Huoponen, S., & Blom, M. (2015). A systematic review of the cost-effectiveness of biologics for the treatment of inflammatory bowel diseases. PLoS ONE. 10(12), e0145087.PubMedPubMedCentral Huoponen, S., & Blom, M. (2015). A systematic review of the cost-effectiveness of biologics for the treatment of inflammatory bowel diseases. PLoS ONE. 10(12), e0145087.PubMedPubMedCentral
19.
go back to reference Pillai, N., Dusheiko, M., Burnand, B., & Pittet, V. (2017). A systematic review of cost-effectiveness studies comparing conventional, biological and surgical interventions for inflammatory bowel disease. PLoS ONE. 12(10), e0185500.PubMedPubMedCentral Pillai, N., Dusheiko, M., Burnand, B., & Pittet, V. (2017). A systematic review of cost-effectiveness studies comparing conventional, biological and surgical interventions for inflammatory bowel disease. PLoS ONE. 12(10), e0185500.PubMedPubMedCentral
20.
go back to reference Rencz, F., Gulacsi, L., Pentek, M., Gecse, K. B., Dignass, A., Halfvarson, J., et al. (2017). Cost-utility of biological treatment sequences for luminal Crohn’s disease in Europe. Expert Review of Pharmacoeconomics & Outcomes Research, 17(6), 597–606. Rencz, F., Gulacsi, L., Pentek, M., Gecse, K. B., Dignass, A., Halfvarson, J., et al. (2017). Cost-utility of biological treatment sequences for luminal Crohn’s disease in Europe. Expert Review of Pharmacoeconomics & Outcomes Research, 17(6), 597–606.
21.
go back to reference Punekar, Y. S., Sunderland, T., Hawkins, N., & Lindsay, J. (2010). Cost-effectiveness of scheduled maintenance treatment with infliximab for pediatric Crohn’s disease. Value in Health, 13(2), 188–195.PubMed Punekar, Y. S., Sunderland, T., Hawkins, N., & Lindsay, J. (2010). Cost-effectiveness of scheduled maintenance treatment with infliximab for pediatric Crohn’s disease. Value in Health, 13(2), 188–195.PubMed
22.
go back to reference Baji, P., Gulácsi, L., Brodszky, V., Végh, Z., Danese, S., Irving, P. M., et al. (2018). Cost-effectiveness of biological treatment sequences for fistulising Crohn’s disease across Europe. United European Gastroenterology Journal, 6(2), 310–321.PubMedPubMedCentral Baji, P., Gulácsi, L., Brodszky, V., Végh, Z., Danese, S., Irving, P. M., et al. (2018). Cost-effectiveness of biological treatment sequences for fistulising Crohn’s disease across Europe. United European Gastroenterology Journal, 6(2), 310–321.PubMedPubMedCentral
23.
go back to reference Malinowski, K. P., & Kawalec, P. (2016). Health utility of patients with Crohn’s disease and ulcerative colitis: A systematic review and meta-analysis. Expert Review of Pharmacoeconomics & Outcomes Research, 16(4), 441–453. Malinowski, K. P., & Kawalec, P. (2016). Health utility of patients with Crohn’s disease and ulcerative colitis: A systematic review and meta-analysis. Expert Review of Pharmacoeconomics & Outcomes Research, 16(4), 441–453.
24.
go back to reference Brooks, R. (2012). The EuroQol group after 25 years. New York: Springer. Brooks, R. (2012). The EuroQol group after 25 years. New York: Springer.
25.
go back to reference Konig, H. H., Ulshofer, A., Gregor, M., von Tirpitz, C., Reinshagen, M., Adler, G., et al. (2002). Validation of the EuroQol questionnaire in patients with inflammatory bowel disease. European Journal of Gastroenterology & Hepatology, 14(11), 1205–1215. Konig, H. H., Ulshofer, A., Gregor, M., von Tirpitz, C., Reinshagen, M., Adler, G., et al. (2002). Validation of the EuroQol questionnaire in patients with inflammatory bowel disease. European Journal of Gastroenterology & Hepatology, 14(11), 1205–1215.
26.
go back to reference Stark, R. G., Reitmeir, P., Leidl, R., & Konig, H. H. (2010). Validity, reliability, and responsiveness of the EQ-5D in inflammatory bowel disease in Germany. Inflammatory Bowel Disease, 16(1), 42–51. Stark, R. G., Reitmeir, P., Leidl, R., & Konig, H. H. (2010). Validity, reliability, and responsiveness of the EQ-5D in inflammatory bowel disease in Germany. Inflammatory Bowel Disease, 16(1), 42–51.
27.
go back to reference Herdman, M., Gudex, C., Lloyd, A., Janssen, M., Kind, P., Parkin, D., et al. (2011). Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L). Quality of Life Research, 20(10), 1727–1736.PubMedPubMedCentral Herdman, M., Gudex, C., Lloyd, A., Janssen, M., Kind, P., Parkin, D., et al. (2011). Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L). Quality of Life Research, 20(10), 1727–1736.PubMedPubMedCentral
28.
go back to reference Janssen, M. F., Pickard, A. S., Golicki, D., Gudex, C., Niewada, M., Scalone, L., et al. (2013). Measurement properties of the EQ-5D-5L compared to the EQ-5D-3L across eight patient groups: A multi-country study. Quality of Life Research, 22(7), 1717–1727.PubMed Janssen, M. F., Pickard, A. S., Golicki, D., Gudex, C., Niewada, M., Scalone, L., et al. (2013). Measurement properties of the EQ-5D-5L compared to the EQ-5D-3L across eight patient groups: A multi-country study. Quality of Life Research, 22(7), 1717–1727.PubMed
29.
go back to reference Buchholz, I., Janssen, M. F., Kohlmann, T., & Feng, Y. S. (2018). A systematic review of studies comparing the measurement properties of the three-level and five-level versions of the EQ-5D. Pharmacoeconomics, 36(6), 645–661.PubMedPubMedCentral Buchholz, I., Janssen, M. F., Kohlmann, T., & Feng, Y. S. (2018). A systematic review of studies comparing the measurement properties of the three-level and five-level versions of the EQ-5D. Pharmacoeconomics, 36(6), 645–661.PubMedPubMedCentral
30.
go back to reference Norton, C., Dibley, L. B., Hart, A., Duncan, J., Emmanuel, A., Knowles, C. H., et al. (2015). Faecal incontinence intervention study (FINS): Self-management booklet information with or without nurse support to improve continence in people with inflammatory bowel disease: Study protocol for a randomized controlled trial. Trials, 16, 444.PubMedPubMedCentral Norton, C., Dibley, L. B., Hart, A., Duncan, J., Emmanuel, A., Knowles, C. H., et al. (2015). Faecal incontinence intervention study (FINS): Self-management booklet information with or without nurse support to improve continence in people with inflammatory bowel disease: Study protocol for a randomized controlled trial. Trials, 16, 444.PubMedPubMedCentral
31.
go back to reference Tew, G. A., Carpenter, R., Seed, M., Anderson, S., Langmead, L., Fairhurst, C., et al. (2017). Feasibility of high-intensity interval training and moderate-intensity continuous training in adults with inactive or mildly active Crohn’s disease: Study protocol for a randomised controlled trial. Pilot and Feasibility Studies, 3, 17.PubMedPubMedCentral Tew, G. A., Carpenter, R., Seed, M., Anderson, S., Langmead, L., Fairhurst, C., et al. (2017). Feasibility of high-intensity interval training and moderate-intensity continuous training in adults with inactive or mildly active Crohn’s disease: Study protocol for a randomised controlled trial. Pilot and Feasibility Studies, 3, 17.PubMedPubMedCentral
32.
go back to reference Pentek, M., Lakatos, P. L., Oorsprong, T., Gulacsi, L., Pavlova, M., Groot, W., et al. (2017). Access to biologicals in Crohn’s disease in ten European countries. World Journal of Gastroenterology, 23(34), 6294–6305.PubMedPubMedCentral Pentek, M., Lakatos, P. L., Oorsprong, T., Gulacsi, L., Pavlova, M., Groot, W., et al. (2017). Access to biologicals in Crohn’s disease in ten European countries. World Journal of Gastroenterology, 23(34), 6294–6305.PubMedPubMedCentral
33.
go back to reference EuroQol, G. (1990). EuroQol–a new facility for the measurement of health-related quality of life. Health Policy, 16(3), 199–208. EuroQol, G. (1990). EuroQol–a new facility for the measurement of health-related quality of life. Health Policy, 16(3), 199–208.
34.
go back to reference Brooks, R. (1996). EuroQol: The current state of play. Health Policy, 37(1), 53–72.PubMed Brooks, R. (1996). EuroQol: The current state of play. Health Policy, 37(1), 53–72.PubMed
35.
go back to reference Poor, A. K., Rencz, F., Brodszky, V., Gulacsi, L., Beretzky, Z., Hidvegi, B., et al. (2017). Measurement properties of the EQ-5D-5L compared to the EQ-5D-3L in psoriasis patients. Quality of Life Research, 26(12), 3409–3419.PubMed Poor, A. K., Rencz, F., Brodszky, V., Gulacsi, L., Beretzky, Z., Hidvegi, B., et al. (2017). Measurement properties of the EQ-5D-5L compared to the EQ-5D-3L in psoriasis patients. Quality of Life Research, 26(12), 3409–3419.PubMed
36.
go back to reference Janssen, M. F., Birnie, E., Haagsma, J. A., & Bonsel, G. J. (2008). Comparing the standard EQ-5D three-level system with a five-level version. Value in Health, 11(2), 275–284.PubMed Janssen, M. F., Birnie, E., Haagsma, J. A., & Bonsel, G. J. (2008). Comparing the standard EQ-5D three-level system with a five-level version. Value in Health, 11(2), 275–284.PubMed
37.
go back to reference van Hout, B., Janssen, M. F., Feng, Y. S., Kohlmann, T., Busschbach, J., Golicki, D., et al. (2012). Interim scoring for the EQ-5D-5L: Mapping the EQ-5D-5L to EQ-5D-3L value sets. Value in Health, 15(5), 708–715.PubMed van Hout, B., Janssen, M. F., Feng, Y. S., Kohlmann, T., Busschbach, J., Golicki, D., et al. (2012). Interim scoring for the EQ-5D-5L: Mapping the EQ-5D-5L to EQ-5D-3L value sets. Value in Health, 15(5), 708–715.PubMed
38.
go back to reference Dolan, P. (1997). Modeling valuations for EuroQol health states. Medical Care, 35(11), 1095–1108.PubMed Dolan, P. (1997). Modeling valuations for EuroQol health states. Medical Care, 35(11), 1095–1108.PubMed
39.
go back to reference Devlin, N. J., Shah, K. K., Feng, Y., Mulhern, B., & van Hout, B. (2018). Valuing health-related quality of life: An EQ-5D-5L value set for England. Health Economics, 27(1), 7–22.PubMed Devlin, N. J., Shah, K. K., Feng, Y., Mulhern, B., & van Hout, B. (2018). Valuing health-related quality of life: An EQ-5D-5L value set for England. Health Economics, 27(1), 7–22.PubMed
40.
go back to reference Winship, D. H., Summers, R. W., Singleton, J. W., Best, W. R., Becktel, J. M., Lenk, L. F., et al. (1979). National Cooperative Crohn’s Disease Study: Study design and conduct of the study. Gastroenterology, 77(4 Pt 2), 829–842.PubMed Winship, D. H., Summers, R. W., Singleton, J. W., Best, W. R., Becktel, J. M., Lenk, L. F., et al. (1979). National Cooperative Crohn’s Disease Study: Study design and conduct of the study. Gastroenterology, 77(4 Pt 2), 829–842.PubMed
41.
go back to reference Sandborn, W. J., Feagan, B. G., Hanauer, S. B., Lochs, H., Lofberg, R., Modigliani, R., et al. (2002). A review of activity indices and efficacy endpoints for clinical trials of medical therapy in adults with Crohn’s disease. Gastroenterology, 122(2), 512–530.PubMed Sandborn, W. J., Feagan, B. G., Hanauer, S. B., Lochs, H., Lofberg, R., Modigliani, R., et al. (2002). A review of activity indices and efficacy endpoints for clinical trials of medical therapy in adults with Crohn’s disease. Gastroenterology, 122(2), 512–530.PubMed
42.
go back to reference Irvine, E. J. (1995). Usual therapy improves perianal Crohn’s disease as measured by a new disease activity index. McMaster IBD Study Group. Journal of Clinical Gastroenterology, 20(1), 27–32.PubMed Irvine, E. J. (1995). Usual therapy improves perianal Crohn’s disease as measured by a new disease activity index. McMaster IBD Study Group. Journal of Clinical Gastroenterology, 20(1), 27–32.PubMed
43.
go back to reference Losco, A., Vigano, C., Conte, D., Cesana, B. M., & Basilisco, G. (2009). Assessing the activity of perianal Crohn’s disease: Comparison of clinical indices and computer-assisted anal ultrasound. Inflammatory Bowel Disease, 15(5), 742–749. Losco, A., Vigano, C., Conte, D., Cesana, B. M., & Basilisco, G. (2009). Assessing the activity of perianal Crohn’s disease: Comparison of clinical indices and computer-assisted anal ultrasound. Inflammatory Bowel Disease, 15(5), 742–749.
44.
go back to reference Ripamonti, C. I. (2012). Pain management. Annals of Oncology, 23(Suppl 10), 294–301. Ripamonti, C. I. (2012). Pain management. Annals of Oncology, 23(Suppl 10), 294–301.
45.
go back to reference Janssen, M. F., Birnie, E., & Bonsel, G. J. (2008). Quantification of the level descriptors for the standard EQ-5D three-level system and a five-level version according to two methods. Quality of Life Research, 17(3), 463–473.PubMedPubMedCentral Janssen, M. F., Birnie, E., & Bonsel, G. J. (2008). Quantification of the level descriptors for the standard EQ-5D three-level system and a five-level version according to two methods. Quality of Life Research, 17(3), 463–473.PubMedPubMedCentral
46.
go back to reference Pickard, A. S., De Leon, M. C., Kohlmann, T., Cella, D., & Rosenbloom, S. (2007). Psychometric comparison of the standard EQ-5D to a 5 level version in cancer patients. Medical Care, 45(3), 259–263.PubMed Pickard, A. S., De Leon, M. C., Kohlmann, T., Cella, D., & Rosenbloom, S. (2007). Psychometric comparison of the standard EQ-5D to a 5 level version in cancer patients. Medical Care, 45(3), 259–263.PubMed
47.
go back to reference Buchholz, I., Thielker, K., Feng, Y. S., Kupatz, P., & Kohlmann, T. (2015). Measuring changes in health over time using the EQ-5D 3L and 5L: A head-to-head comparison of measurement properties and sensitivity to change in a German inpatient rehabilitation sample. Quality of Life Research, 24(4), 829–835.PubMed Buchholz, I., Thielker, K., Feng, Y. S., Kupatz, P., & Kohlmann, T. (2015). Measuring changes in health over time using the EQ-5D 3L and 5L: A head-to-head comparison of measurement properties and sensitivity to change in a German inpatient rehabilitation sample. Quality of Life Research, 24(4), 829–835.PubMed
48.
go back to reference Shrout, P. E., & Fleiss, J. L. (1979). Intraclass correlations: Uses in assessing rater reliability. Psychological Bulletin, 86(2), 420–428.PubMed Shrout, P. E., & Fleiss, J. L. (1979). Intraclass correlations: Uses in assessing rater reliability. Psychological Bulletin, 86(2), 420–428.PubMed
49.
go back to reference Cicchetti, D. (1994). Guidelines, criteria, and rules of thumb for evaluating normed and standardized assessment instruments in psychology. Psychological Assessment, 6(4), 284–290. Cicchetti, D. (1994). Guidelines, criteria, and rules of thumb for evaluating normed and standardized assessment instruments in psychology. Psychological Assessment, 6(4), 284–290.
50.
go back to reference Bland, J. M., & Altman, D. G. (1986). Statistical methods for assessing agreement between two methods of clinical measurement. The Lancet, 1(8476), 307–310. Bland, J. M., & Altman, D. G. (1986). Statistical methods for assessing agreement between two methods of clinical measurement. The Lancet, 1(8476), 307–310.
51.
go back to reference Shannon, C. E. (1948). The mathematical theory of communication. The Bell System Technical Journal, 27, 379–423. Shannon, C. E. (1948). The mathematical theory of communication. The Bell System Technical Journal, 27, 379–423.
52.
go back to reference Shannon, C. E., & Weaver, W. (1949). The mathematical theory of communication. Urbana: University of Illinois Press, pp. 104–107. Shannon, C. E., & Weaver, W. (1949). The mathematical theory of communication. Urbana: University of Illinois Press, pp. 104–107.
53.
go back to reference Swinscow, T., & Campbell, M. (2002). Statistics at square one. London: BMJ. Swinscow, T., & Campbell, M. (2002). Statistics at square one. London: BMJ.
54.
go back to reference Ferreira, L. N., Ferreira, P. L., Ribeiro, F. P., & Pereira, L. N. (2016). Comparing the performance of the EQ-5D-3L and the EQ-5D-5L in young Portuguese adults. Health and Quality of Life Outcomes, 14(1), 89.PubMedPubMedCentral Ferreira, L. N., Ferreira, P. L., Ribeiro, F. P., & Pereira, L. N. (2016). Comparing the performance of the EQ-5D-3L and the EQ-5D-5L in young Portuguese adults. Health and Quality of Life Outcomes, 14(1), 89.PubMedPubMedCentral
55.
go back to reference Yfantopoulos, J., Chantzaras, A., & Kontodimas, S. (2017). Assessment of the psychometric properties of the EQ-5D-3L and EQ-5D-5L instruments in psoriasis. Archives of Dermatological Research, 309(5), 357–370.PubMed Yfantopoulos, J., Chantzaras, A., & Kontodimas, S. (2017). Assessment of the psychometric properties of the EQ-5D-3L and EQ-5D-5L instruments in psoriasis. Archives of Dermatological Research, 309(5), 357–370.PubMed
56.
go back to reference Scalone, L., Ciampichini, R., Fagiuoli, S., Gardini, I., Fusco, F., Gaeta, L., et al. (2013). Comparing the performance of the standard EQ-5D 3L with the new version EQ-5D 5L in patients with chronic hepatic diseases. Quality of Life Research, 22(7), 1707–1716.PubMed Scalone, L., Ciampichini, R., Fagiuoli, S., Gardini, I., Fusco, F., Gaeta, L., et al. (2013). Comparing the performance of the standard EQ-5D 3L with the new version EQ-5D 5L in patients with chronic hepatic diseases. Quality of Life Research, 22(7), 1707–1716.PubMed
57.
go back to reference Jia, Y. X., Cui, F. Q., Li, L., Zhang, D. L., Zhang, G. M., Wang, F. Z., et al. (2014). Comparison between the EQ-5D-5L and the EQ-5D-3L in patients with hepatitis B. Quality of Life Research, 23(8), 2355–2363.PubMed Jia, Y. X., Cui, F. Q., Li, L., Zhang, D. L., Zhang, G. M., Wang, F. Z., et al. (2014). Comparison between the EQ-5D-5L and the EQ-5D-3L in patients with hepatitis B. Quality of Life Research, 23(8), 2355–2363.PubMed
58.
go back to reference Pan, C. W., Sun, H. P., Wang, X., Ma, Q., Xu, Y., Luo, N., et al. (2015). The EQ-5D-5L index score is more discriminative than the EQ-5D-3L index score in diabetes patients. Quality of Life Research, 24(7), 1767–1774.PubMed Pan, C. W., Sun, H. P., Wang, X., Ma, Q., Xu, Y., Luo, N., et al. (2015). The EQ-5D-5L index score is more discriminative than the EQ-5D-3L index score in diabetes patients. Quality of Life Research, 24(7), 1767–1774.PubMed
59.
go back to reference Kim, S. H., Kim, H. J., Lee, S. I., & Jo, M. W. (2012). Comparing the psychometric properties of the EQ-5D-3L and EQ-5D-5L in cancer patients in Korea. Quality of Life Research, 21(6), 1065–1073.PubMed Kim, S. H., Kim, H. J., Lee, S. I., & Jo, M. W. (2012). Comparing the psychometric properties of the EQ-5D-3L and EQ-5D-5L in cancer patients in Korea. Quality of Life Research, 21(6), 1065–1073.PubMed
60.
go back to reference Golicki, D., Niewada, M., Karlinska, A., Buczek, J., Kobayashi, A., Janssen, M. F., et al. (2015). Comparing responsiveness of the EQ-5D-5L, EQ-5D-3L and EQ VAS in stroke patients. Quality of Life Research, 24(6), 1555–1563.PubMed Golicki, D., Niewada, M., Karlinska, A., Buczek, J., Kobayashi, A., Janssen, M. F., et al. (2015). Comparing responsiveness of the EQ-5D-5L, EQ-5D-3L and EQ VAS in stroke patients. Quality of Life Research, 24(6), 1555–1563.PubMed
61.
go back to reference Greene, M. E., Rader, K. A., Garellick, G., Malchau, H., Freiberg, A. A., & Rolfson, O. (2015). The EQ-5D-5L improves on the EQ-5D-3L for health-related quality-of-life assessment in patients undergoing total hip arthroplasty. Clinical Orthopaedics and Related Research, 473(11), 3383–3390.PubMed Greene, M. E., Rader, K. A., Garellick, G., Malchau, H., Freiberg, A. A., & Rolfson, O. (2015). The EQ-5D-5L improves on the EQ-5D-3L for health-related quality-of-life assessment in patients undergoing total hip arthroplasty. Clinical Orthopaedics and Related Research, 473(11), 3383–3390.PubMed
62.
go back to reference Buxton, M. J., Lacey, L. A., Feagan, B. G., Niecko, T., Miller, D. W., & Townsend, R. J. (2007). Mapping from disease-specific measures to utility: An analysis of the relationships between the Inflammatory Bowel Disease Questionnaire and Crohn’s Disease Activity Index in Crohn’s disease and measures of utility. Value in Health, 10(3), 214–220.PubMed Buxton, M. J., Lacey, L. A., Feagan, B. G., Niecko, T., Miller, D. W., & Townsend, R. J. (2007). Mapping from disease-specific measures to utility: An analysis of the relationships between the Inflammatory Bowel Disease Questionnaire and Crohn’s Disease Activity Index in Crohn’s disease and measures of utility. Value in Health, 10(3), 214–220.PubMed
63.
go back to reference de Dombal, F. T., & Softley, A. (1987). IOIBD report no 1: Observer variation in calculating indices of severity and activity in Crohn’s disease. International Organisation for the Study of Inflammatory Bowel Disease. Gut, 28(4), 474–481.PubMedPubMedCentral de Dombal, F. T., & Softley, A. (1987). IOIBD report no 1: Observer variation in calculating indices of severity and activity in Crohn’s disease. International Organisation for the Study of Inflammatory Bowel Disease. Gut, 28(4), 474–481.PubMedPubMedCentral
64.
go back to reference Khanna, R., Nelson, S. A., Feagan, B. G., D’Haens, G., Sandborn, W. J., Zou, G. Y., et al. (2016). Endoscopic scoring indices for evaluation of disease activity in Crohn’s disease. Cochrane Database of Systematic Reviews, 8, CD010642. Khanna, R., Nelson, S. A., Feagan, B. G., D’Haens, G., Sandborn, W. J., Zou, G. Y., et al. (2016). Endoscopic scoring indices for evaluation of disease activity in Crohn’s disease. Cochrane Database of Systematic Reviews, 8, CD010642.
65.
go back to reference Peyrin-Biroulet, L., Panes, J., Sandborn, W. J., Vermeire, S., Danese, S., Feagan, B. G., et al. (2016). Defining disease severity in inflammatory bowel diseases: Current and future directions. Clinical Gastroenterology and Hepatology, 14(3), 348–354 e317.PubMed Peyrin-Biroulet, L., Panes, J., Sandborn, W. J., Vermeire, S., Danese, S., Feagan, B. G., et al. (2016). Defining disease severity in inflammatory bowel diseases: Current and future directions. Clinical Gastroenterology and Hepatology, 14(3), 348–354 e317.PubMed
66.
go back to reference Regueiro, M., Kip, K. E., Schraut, W., Baidoo, L., Sepulveda, A. R., Pesci, M., et al. (2011). Crohn’s disease activity index does not correlate with endoscopic recurrence one year after ileocolonic resection. Inflammatory Bowel Disease, 17(1), 118–126. Regueiro, M., Kip, K. E., Schraut, W., Baidoo, L., Sepulveda, A. R., Pesci, M., et al. (2011). Crohn’s disease activity index does not correlate with endoscopic recurrence one year after ileocolonic resection. Inflammatory Bowel Disease, 17(1), 118–126.
67.
go back to reference Mulhern, B., Feng, Y., Shah, K., Janssen, M. F., Herdman, M., van Hout, B., et al. (2018). Comparing the UK EQ-5D-3L and english EQ-5D-5L value sets. Pharmacoeconomics, 36(6), 699–713.PubMedPubMedCentral Mulhern, B., Feng, Y., Shah, K., Janssen, M. F., Herdman, M., van Hout, B., et al. (2018). Comparing the UK EQ-5D-3L and english EQ-5D-5L value sets. Pharmacoeconomics, 36(6), 699–713.PubMedPubMedCentral
68.
go back to reference Devlin, N., Brazier, J., Pickard, A. S., & Stolk, E. (2018). 3L, 5L, What the L? A NICE Conundrum. Pharmacoeconomics, 36(6), 637–640.PubMedPubMedCentral Devlin, N., Brazier, J., Pickard, A. S., & Stolk, E. (2018). 3L, 5L, What the L? A NICE Conundrum. Pharmacoeconomics, 36(6), 637–640.PubMedPubMedCentral
69.
go back to reference Hernandez Alava, M., Wailoo, A., Grimm, S., Pudney, S., Gomes, M., Sadique, Z., et al. (2018). EQ-5D-5L versus EQ-5D-3L: The Impact on Cost Effectiveness in the United Kingdom. Value in Health, 21(1), 49–56.PubMed Hernandez Alava, M., Wailoo, A., Grimm, S., Pudney, S., Gomes, M., Sadique, Z., et al. (2018). EQ-5D-5L versus EQ-5D-3L: The Impact on Cost Effectiveness in the United Kingdom. Value in Health, 21(1), 49–56.PubMed
70.
go back to reference Janssen, M. F., Bonsel, G. J., & Luo, N. (2018). Is EQ-5D-5L better than EQ-5D-3L? A head-to-head comparison of descriptive systems and value sets from seven countries. Pharmacoeconomics, 36(6), 675–697. Janssen, M. F., Bonsel, G. J., & Luo, N. (2018). Is EQ-5D-5L better than EQ-5D-3L? A head-to-head comparison of descriptive systems and value sets from seven countries. Pharmacoeconomics, 36(6), 675–697.
Metagegevens
Titel
Validity of the EQ-5D-5L and EQ-5D-3L in patients with Crohn’s disease
Auteurs
Fanni Rencz
Peter L. Lakatos
László Gulácsi
Valentin Brodszky
Zsuzsanna Kürti
Szilvia Lovas
János Banai
László Herszényi
Tamás Cserni
Tamás Molnár
Márta Péntek
Károly Palatka
Publicatiedatum
17-09-2018
Uitgeverij
Springer International Publishing
Gepubliceerd in
Quality of Life Research / Uitgave 1/2019
Print ISSN: 0962-9343
Elektronisch ISSN: 1573-2649
DOI
https://doi.org/10.1007/s11136-018-2003-4